Bluejay Diagnostics, Inc. (BJDX) - 10-K Summary
Business Context and Reporting Period
Company: Bluejay Diagnostics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Bluejay is a clinical-stage medical diagnostics company developing the "Symphony" platform, a rapid, near-patient testing system for critical care settings, specifically targeting sepsis via an IL-6 biomarker test. The company has no approved products and generates no revenue. It relies on licensed intellectual property from Toray Industries and contract manufacturing by Sanyoseiko Co., Ltd.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(6.85) million | $(7.72) million |
| Operating Expenses | $(6.95) million | $(7.17) million |
| Cash and Cash Equivalents (Dec 31, 2025) | $5.16 million | $4.30 million |
| Accumulated Deficit | $(41.52) million | $(34.67) million |
| Current Liabilities | $1.12 million | $0.81 million |
| Stockholders' Equity | $5.98 million | $5.73 million |
Note: The 2024 net loss applicable to common shareholders was significantly higher ($(20.94) million) due to a non-cash deemed dividend of $13.22 million resulting from warrant modifications.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased by approximately $0.22 million (3%) year-over-year. Research and Development (R&D) expenses declined by 12% ($0.43 million) due to reduced technology transfer efforts, partially offset by increased clinical trial costs. General and Administrative (G&A) expenses increased by 6% ($0.22 million), driven by higher Delaware franchise taxes and personnel costs.
- Other Income/Expense: Total other income improved from a net expense of $(0.55) million in 2024 to net income of $0.10 million in 2025. This was primarily due to the absence of significant interest expense associated with the 2024 Bridge Note Financing, which was repaid in full.
- Cash Flow: Net cash used in operating activities decreased to $(6.05) million in 2025 from $(7.82) million in 2024. Net cash provided by financing activities decreased to $7.09 million in 2025 from $10.22 million in 2024, reflecting a shift from public offerings in 2024 to private placements in 2025.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: The filing includes an "Emphasis of Matter" regarding going concern. Management estimates current cash resources will fund operations only through the third quarter of 2026. The company expects to require at least $20 million in additional capital by the end of fiscal 2027 to complete clinical trials and submit a 510(k) application to the FDA.
- Clinical Progress: The company is enrolling patients in the SYMON-II pivotal clinical trial (target: 750 patients; enrolled: ~583 as of filing date). Enrollment is expected to complete in summer 2026. Testing of samples is delayed pending resolution of manufacturing reproducibility issues with Symphony cartridges.
- Manufacturing Risks: The company is working with Sanyoseiko to modify cartridge manufacturing processes. Failure to resolve technical issues or establish an alternative manufacturing site by October 2026 could result in termination of the license agreement with Toray, which is critical to the company's viability.
- Capital Structure Risks: The company has undergone four reverse stock splits since 2023 (aggregate 1-for-32,000). Outstanding warrants represent a significant number of shares relative to the current outstanding common stock, creating substantial dilution risk. The stock price has fallen over 99.9% since the IPO.
- Regulatory Risks: There is no assurance that the SYMON-II trial will validate the IL-6 cutoff values or that the FDA will grant 510(k) clearance. The company faces potential delisting from Nasdaq if it fails to meet market value or bid price requirements.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to raise the required $20 million before the projected cash exhaustion in Q3 2026.
- Manufacturing Resolution: Confirm the status of the cartridge manufacturing reproducibility issues and the timeline for establishing the alternative manufacturing site required by the Toray license agreement (deadline: October 2026).
- Clinical Trial Enrollment: Monitor the completion of the SYMON-II trial enrollment (target 750 patients) and the subsequent timeline for sample testing and data analysis.
- Dilution Impact: Assess the potential dilution from the large number of outstanding warrants (over 1.5 million shares underlying warrants vs. ~972,000 shares outstanding) and the terms of future fundraising.
- Nasdaq Compliance: Monitor the stock price relative to the $1.00 minimum bid price and the proposed $5 million market value listing requirement to assess delisting risk.